Biocon Chooses To Settle Over Eylea In US – Will Others Follow?
Biosimilars Giant Secures H2 2026 Launch Date For Yesafili Version Of Aflibercept
After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?
